Corcept Therapeutics Incorporated (CORT)

Market Cap	6.13B
Revenue (ttm)	628.56M
Net Income (ttm)	140.49M
Shares Out	104.78M
EPS (ttm)	1.26
PE Ratio	46.45
Forward PE	35.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,647
Open	58.89
Previous Close	59.21
Day's Range	57.88 - 59.15
52-Week Range	20.84 - 61.66
Beta	0.52
Analysts	Strong Buy
Price Target	75.25 (+28.59%)
Earnings Date	Oct 30, 2024

About CORT

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 352
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT
• Website: https://www.corcept.com

Financial Performance

In 2023, Corcept Therapeutics's revenue was $482.38 million, an increase of 20.04% compared to the previous year's $401.86 million. Earnings were $105.50 million, an increase of 4.15%.

Analyst Forecast

According to 4 analysts, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $75.25, which is an increase of 28.59% from the latest price.

Price Target

$75.25

(28.59% upside)

Analyst Consensus: Strong Buy